The HYLAN M Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial

Dry Eye Disease

High Molecular Weight Hyaluronan Promotes Corneal Nerve Growth in Severe Dry Eyes

J Clin Med

van Setten GB, Stachs O, Dupas B, Turhan SA, Seitz B, Reitsamer H, Winter K, Horwath-Winter J, Guthoff RF, Müller-Lierheim WGK

doi: 10.3390/jcm9123799

Dry Eye Disease

A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease

Ophthalmology.

Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD

doi: 10.1016/j.ophtha.

Further PublicationsDry Eye Disease

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials

JAMA Ophthalmol

Holland EJ, Jackson MA, Donnenfeld E, Piccolo R, Cohen A, Barabino S, Rolando M, Figueiredo FC

doi: 10.1001/jamaophthalmol.2021.3943

Dry Eye Disease

Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease

Invest Ophthalmol Vis Sci.

Cohn GS, Corbett D, Tenen A, Coroneo M, McAlister J, Craig JP, Gray T, Kent D, Murray N, Petsoglou C, Baba SN, Holland EJ

doi: 10.1167/iovs.18-23984.

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease

Eur J Ophthalmol.

Nichols KK, Donnenfeld ED, Karpecki PM, Hovanesian JA, Raychaudhuri A, Shojaei A, Zhang S

doi: 10.1177/1120672118791936.

Dry Eye Disease

Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial

Ophthalmology

Wirta D, Vollmer P, Paauw J, Chiu KH, Henry E, Striffler K, Nau J, ONSET-2 Study Group.

doi: 10.1016/j.ophtha.2021.11.004

Dry Eye Disease

The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease

Ocul Surf.

Hussain M, Shtein RM, Pistilli M, Maguire MG, Oydanich M, Asbell PA, DREAM Research Group.

doi: 10.1016/j.jtos.2019.08.002.

Dry Eye Disease

An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial

Ocul Surf.

Downie LE, Hom MM, Berdy GJ, El-Harazi S, Verachtert A, Tan J, Liu H, Carlisle-Wilcox C, Simmons P, Vehige J

doi: 10.1016/j.jtos.2019.11.004.

Dry Eye Disease

Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review

Ocul Surf.

Holland EJ, Darvish M, Nichol KK, Jones L, Karpecki PM

doi: 10.1016/j.jtos.2019.02.012.

Related content

High Molecular Weight Hyaluronan Promotes Corneal Nerve Growth in Severe Dry Eyes

A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials

Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease

Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial

The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease

An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial

Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review